A Novel Treatment Strategy for Patients with Intermediate-Stage HCC Who Are Not Suitable for TACE: Upfront Systemic Therapy Followed by Curative Conversion
Saved in:
Main Author: | Masatoshi Kudo |
---|---|
Format: | article |
Language: | EN |
Published: |
Karger Publishers
2021
|
Subjects: | |
Online Access: | https://doaj.org/article/3b527f3351db4053af3b26a90b2bfcec |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Changing the Treatment Paradigm for Hepatocellular Carcinoma Using Atezolizumab plus Bevacizumab Combination Therapy
by: Masatoshi Kudo
Published: (2021) -
Hepatocarcinoma con invasión cardiovascular: comunicación de 5 casos y revisión de la literatura
by: Valera M,José M, et al.
Published: (2004) -
The Efficacy and Prognostic Factors of the Combination of TACE and Apatinib for the Treatment of BCLC Stage C Hepatocellular Carcinoma
by: Shun Liu, et al.
Published: (2021) -
Hepatocarcinoma, porfiria y hemosiderosis. Una asociación no reportada en nuestro país: Caso clínico
by: WHITTLE,CAROLINA, et al.
Published: (2010) -
Carcinoma hepatocelular variedad fibrolamelar metastásico en menores de 20 años: Reporte de 2 casos tratados con intención curativa y revisión de la literatura
by: Butte,Jean M, et al.
Published: (2009)